NEW RELEASES

NEW RELEASES :- Pharmatimes

Thomas Farrell February 4, 2026
NanoSyrinx has appointed Thomas Farrell as CEO and Director
John Pinching
Ahmed Moussa February 4, 2026
Ahmed Moussa is the new Sanofi Country Lead for UK & Ireland
John Pinching
Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay February 3, 2026
The company will initially develop a vaccine to tackle colorectal and pancreatic cancers
Esme Needham
IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease February 3, 2026
Perovial is the first ever hyaluronic acid injectable treatment to be licensed for acute Peyronie’s disease
Esme Needham
En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation February 2, 2026
The US sees around 476,000 new Lyme cases every year
Esme Needham
ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children February 2, 2026
Anaphylaxis is the most serious type of allergic reaction and occurs more commonly in boys
Esme Needham
CERo reports encouraging early data from phase 1 trial of CER‑1236 January 29, 2026
CER‑T therapy shows initial safety signals and prompts protocol expansion
John Pinching
ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray January 29, 2026
Trial to assess whether once‑weekly treatment can reduce symptomatic viral respiratory infections
John Pinching
Argo Biopharma doses first patient in phase 2b trial of BW‑20829 January 28, 2026
siRNA therapeutic progresses in global study for patients with elevated Lp(a)
John Pinching
Akari files new patent and advances second ADC targeting CEACAM5 January 28, 2026
Company strengthens pipeline with AKTX-102 as it broadens its intellectual property estate
John Pinching

[wp-rss-aggregator feeds="pharmexec-com"]

[wp-rss-aggregator feeds="pharmiweb-com-articles"]

Thomas Farrell
NanoSyrinx has appointed Thomas Farrell as CEO and Director
Ahmed Moussa
Ahmed Moussa is the new Sanofi Country Lead for UK & Ireland
Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
The company will initially develop a vaccine to tackle colorectal and pancreatic cancers
IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
Perovial is the first ever hyaluronic acid injectable treatment to be licensed for acute Peyronie’s disease
En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
The US sees around 476,000 new Lyme cases every year
ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
Anaphylaxis is the most serious type of allergic reaction and occurs more commonly in boys
CERo reports encouraging early data from phase 1 trial of CER‑1236
CER‑T therapy shows initial safety signals and prompts protocol expansion
ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
Trial to assess whether once‑weekly treatment can reduce symptomatic viral respiratory infections
Argo Biopharma doses first patient in phase 2b trial of BW‑20829
siRNA therapeutic progresses in global study for patients with elevated Lp(a)
Akari files new patent and advances second ADC targeting CEACAM5
Company strengthens pipeline with AKTX-102 as it broadens its intellectual property estate

GMP and Quality

Non-conformances in Pharmaceutical Laboratories

Pharma VedMay 8, 2024

Pharmaceutical quality control laboratories are the guardians of public health. Through meticulous testing of raw materials, in-process materials, and finished products, they ensure the safety and efficacy of medications. However, nonconformances can arise...